Drug Shortage Report for PAZEO
Report ID | 114100 |
Drug Identification Number | 02458551 |
Brand name | PAZEO |
Common or Proper name | PAZEO 0.7% SOLUTION 2.5ML |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | OLOPATADINE |
Strength(s) | 0.7% |
Dosage form(s) | SOLUTION |
Route of administration | OPHTHALMIC OPHTHALMIC |
Packaging size | 2.5 ML |
ATC code | S01GX |
ATC description | DECONGESTANTS AND ANTIALLERGICS |
Reason for shortage | Delay in shipping of the drug. |
Anticipated start date | 2020-04-23 |
Actual start date | 2020-04-23 |
Estimated end date | 2020-05-19 |
Actual end date | 2020-05-20 |
Shortage status | Resolved |
Updated date | 2020-05-21 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-05-05 | English | Compare |
v2 | 2020-05-05 | English | Compare |
v3 | 2020-05-05 | French | Compare |
v4 | 2020-05-21 | English | Compare |
v5 | 2020-05-21 | French | Compare |
Showing 1 to 5 of 5